Is ERCC1 a prognostic biomarker for urothelial cancer following radical cystectomy? A long-term analysis

Cent European J Urol. 2021;74(3):348-354. doi: 10.5173/ceju.2021.0043. Epub 2021 Sep 23.

Abstract

Introduction: Excision repair cross-complementation 1 protein (ERCC1) plays a vital role in cancer cells enabling DNA repair via nucleotide excision repair. Thus, we hypothesized whether expression of this protein may be utilized as a prognostic marker in patients after radical cystectomy.

Material and methods: The final analysis involved 123 patients with urothelial bladder carcinoma who underwent radical cystectomy with bilateral lymphadenectomy. The median follow-up time was equal to 853 days. ERCC1 status was evaluated immunohistochemically with the application of tissue microarrays.

Results: Positive ERCC1 expression was noted in 46% of the studied cases. Among the analyzed clinical and pathological factors, we could not establish a statistically significant correlation with ERCC1. Similarly, survival curves were statistically indifferent in patients with tumors categorized according to both expression categories. We did not confirm a prognostic value of ERCC1 in the multivariate regression analysis.

Conclusions: ERCC1 expression does not influence the overall survival of patients with urothelial bladder carcinoma after radical cystectomy.

Keywords: ERCC1 expression; bladder cancer; radical cystectomy; urothelial carcinoma.